دورية أكاديمية
أعرض في EDS

Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review.

التفاصيل البيبلوغرافية
العنوان: Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review.
المؤلفون: Rijs Z; Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Shifai AN; Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Bosma SE; Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Kuppen PJK; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Keereweer S; Department of Otorhinolaryngology Head and Neck Surgery, Erasmus Medical Center Cancer Institute, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands., Bovée JVMG; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., van de Sande MAJ; Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Sier CFM; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.; Percuros BV, Zernikedreef 8, 2333 CL Leiden, The Netherlands., van Driel PBAA; Department of Orthopedic Surgery, Isala Hospital, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
المصدر: Cancers [Cancers (Basel)] 2021 Feb 01; Vol. 13 (3). Date of Electronic Publication: 2021 Feb 01.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Surgery is the mainstay of treatment for localized soft tissue sarcomas (STS). The curative treatment highly depends on complete tumor resection, as positive margins are associated with local recurrence (LR) and prognosis. However, determining the tumor margin during surgery is challenging. Real-time tumor-specific imaging can facilitate complete resection by visualizing tumor tissue during surgery. Unfortunately, STS specific tracers are presently not clinically available. In this review, STS-associated cell surface-expressed biomarkers, which are currently already clinically targeted with monoclonal antibodies for therapeutic purposes, are evaluated for their use in near-infrared fluorescence (NIRF) imaging of STS. Clinically targeted biomarkers in STS were extracted from clinical trial registers and a PubMed search was performed. Data on biomarker characteristics, sample size, percentage of biomarker-positive STS samples, pattern of biomarker expression, biomarker internalization features, and previous applications of the biomarker in imaging were extracted. The biomarkers were ranked utilizing a previously described scoring system. Eleven cell surface-expressed biomarkers were identified from which 7 were selected as potential biomarkers for NIRF imaging: TEM1, VEGFR-1, EGFR, VEGFR-2, IGF-1R, PDGFRα, and CD40. Promising biomarkers in common and aggressive STS subtypes are TEM1 for myxofibrosarcoma, TEM1, and PDGFRα for undifferentiated soft tissue sarcoma and EGFR for synovial sarcoma.
References: PLoS One. 2016 Jun 10;11(6):e0156949. (PMID: 27285994)
Hum Pathol. 2013 Oct;44(10):2302-11. (PMID: 24054722)
Mol Pathol. 1999 Feb;52(1):32-6. (PMID: 10439837)
Am J Surg Pathol. 2006 Apr;30(4):450-6. (PMID: 16625090)
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290. (PMID: 28404198)
Cancer Res. 2017 Aug 15;77(16):4279-4292. (PMID: 28634201)
Pathology. 2017 Aug;49(5):506-513. (PMID: 28688724)
Ann Surg. 1987 Apr;205(4):349-59. (PMID: 3566372)
Br J Haematol. 2003 May;121(3):458-61. (PMID: 12716368)
PLoS One. 2014 Sep 22;9(9):e107146. (PMID: 25243742)
Pathol Res Pract. 2019 Dec;215(12):152700. (PMID: 31704149)
Ann Surg Oncol. 2016 Jul;23(7):2220-8. (PMID: 26847678)
Gynecol Oncol. 2020 Mar;156(3):734-743. (PMID: 31928804)
Histopathology. 2005 May;46(5):522-31. (PMID: 15842634)
Genet Mol Biol. 2020 Jan 17;42(4):e20180391. (PMID: 31967634)
Mol Cancer Ther. 2018 Nov;17(11):2329-2340. (PMID: 30166401)
Oncotarget. 2019 Jan 29;10(9):993-1009. (PMID: 30847027)
JAMA. 2020 Apr 7;323(13):1266-1276. (PMID: 32259228)
Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20. (PMID: 7449206)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Ann Surg Oncol. 2013 Jan;20(1):80-6. (PMID: 22890594)
Virchows Arch. 2019 Feb;474(2):201-207. (PMID: 30483955)
Oncotarget. 2016 Mar 15;7(11):13082-92. (PMID: 26909615)
Ann Rehabil Med. 2013 Apr;37(2):202-7. (PMID: 23705114)
Am J Pathol. 1996 May;148(5):1387-96. (PMID: 8623911)
Clin Sarcoma Res. 2020 May 6;10:9. (PMID: 32391141)
Ann Surg Oncol. 2018 Jul;25(7):1880-1888. (PMID: 29667116)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
F1000Res. 2016 Sep 08;5:. (PMID: 27635238)
Cancer. 2014 Aug 15;120(16):2448-56. (PMID: 24797726)
Gynecol Obstet Invest. 2017;82(4):329-339. (PMID: 28125812)
Mol Imaging Biol. 2017 Aug;19(4):512-521. (PMID: 27909986)
Eur J Gynaecol Oncol. 2012;33(6):629-32. (PMID: 23327060)
Int J Oncol. 2011 Jul;39(1):73-89. (PMID: 21537839)
PLoS One. 2020 Apr 15;15(4):e0222551. (PMID: 32294103)
J Thromb Haemost. 2003 Jan;1(1):164-70. (PMID: 12871554)
Eur J Cancer. 2020 Jun;132:35-42. (PMID: 32325418)
J Pathol. 2007 Jun;212(2):227-35. (PMID: 17471466)
Cancer. 2019 Jul 15;125(14):2445-2454. (PMID: 31034598)
Hum Pathol. 2015 Mar;46(3):357-65. (PMID: 25540867)
Am J Surg Pathol. 2019 Jun;43(6):792-801. (PMID: 31009388)
Adv Mater. 2012 Aug 2;24(29):3981-7. (PMID: 22689074)
Cancer. 2014 Jul 15;120(14):2164-73. (PMID: 24752867)
Cancer Res. 1999 Aug 1;59(15):3588-91. (PMID: 10446966)
Drugs Today (Barc). 2005 Feb;41(2):107-27. (PMID: 15821783)
ESMO Open. 2019 Jun 12;4(Suppl 3):e000510. (PMID: 31275618)
Cancer Res. 2001 Jan 15;61(2):577-81. (PMID: 11212252)
Arch Gynecol Obstet. 2013 Aug;288(2):385-91. (PMID: 23435725)
Expert Rev Anticancer Ther. 2007 May;7(5):725-33. (PMID: 17492935)
Lancet Oncol. 2019 Jul;20(7):e354-e367. (PMID: 31267970)
Eur J Cancer. 2018 Feb;90:111-121. (PMID: 29304474)
J Transl Med. 2018 Nov 6;16(1):303. (PMID: 30400799)
J Pathol. 2008 Dec;216(4):428-39. (PMID: 18855347)
Oncol Rep. 2008 Aug;20(2):309-18. (PMID: 18636191)
Int J Gynecol Pathol. 2012 Nov;31(6):570-9. (PMID: 23018215)
Anticancer Res. 2005 Sep-Oct;25(5):3591-6. (PMID: 16101185)
Cancer Res. 2010 Sep 15;70(18):7304-14. (PMID: 20685895)
Proc SPIE Int Soc Opt Eng. 2016 Apr 17;9836:. (PMID: 27313332)
Am J Clin Oncol. 2018 Sep;41(9):827-831. (PMID: 28640064)
Intern Emerg Med. 2007 Dec;2(4):256-68. (PMID: 18043876)
Lancet Oncol. 2010 Feb;11(2):129-35. (PMID: 20036194)
Int J Gynecol Cancer. 2013 Jan;23(1):81-9. (PMID: 23221606)
Hum Pathol. 2003 Sep;34(9):835-40. (PMID: 14562277)
Int J Gynecol Cancer. 2006 Mar-Apr;16(2):849-53. (PMID: 16681772)
Cancers (Basel). 2019 Dec 21;12(1):. (PMID: 31877801)
J Invest Dermatol. 2019 Oct;139(10):2204-2214.e7. (PMID: 30986375)
Turk Patoloji Derg. 2017;1(1):192-197. (PMID: 28832074)
Mod Pathol. 2006 Sep;19(9):1213-20. (PMID: 16729016)
Mol Imaging Biol. 2011 Dec;13(6):1173-82. (PMID: 21042865)
Cancer. 2017 Sep 1;123(17):3291-3304. (PMID: 28463396)
Pol J Pathol. 2009;60(1):10-8. (PMID: 19670699)
J Pathol. 2012 Jun;227(2):223-33. (PMID: 22294416)
Clin Exp Metastasis. 2014 Jan;31(1):15-24. (PMID: 23877430)
PLoS One. 2010 Dec 14;5(12):e15368. (PMID: 21179485)
Onco Targets Ther. 2018 Feb 16;11:833-842. (PMID: 29497315)
Ann Transl Med. 2019 Aug;7(16):387. (PMID: 31555701)
Sarcoma. 2004;8(1):1-6. (PMID: 18521386)
J Cell Biochem. 2019 Jun;120(6):10239-10247. (PMID: 30609118)
Br J Cancer. 1997;75(11):1631-40. (PMID: 9184179)
Cancer. 2017 Sep 1;123(17):3285-3290. (PMID: 28440953)
Eur J Cancer. 2012 Nov;48(16):3027-35. (PMID: 22682017)
Biomed Res Int. 2013;2013:546318. (PMID: 23986907)
Am J Physiol Renal Physiol. 2008 Jul;295(1):F60-72. (PMID: 18463314)
Anticancer Res. 2019 Jul;39(7):3669-3675. (PMID: 31262893)
Clin Cancer Res. 2015 Aug 15;21(16):3658-66. (PMID: 25904751)
Mod Pathol. 2010 Apr;23(4):574-80. (PMID: 20118913)
J Biomed Sci. 2020 Apr 15;27(1):52. (PMID: 32295602)
Pathol Res Pract. 2015 Oct;211(10):726-30. (PMID: 26298629)
Sci Rep. 2020 Jun 3;10(1):9077. (PMID: 32493964)
Theranostics. 2018 Oct 6;8(18):5178-5199. (PMID: 30429893)
Virchows Arch. 2015 Aug;467(2):211-6. (PMID: 25940995)
Clin Cancer Res. 2018 Jan 15;24(2):316-325. (PMID: 29084918)
Am J Surg Pathol. 2005 Apr;29(4):485-9. (PMID: 15767802)
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12. (PMID: 25210080)
BMC Cancer. 2016 Jul 08;16:434. (PMID: 27393385)
Cancer Res. 2012 Sep 1;72(17):4515-25. (PMID: 22787122)
Hepatology. 2018 Feb;67(2):762-773. (PMID: 28671339)
Methods Mol Biol. 2017;1652:3-35. (PMID: 28791631)
Clin Cancer Res. 2007 Feb 15;13(4):1083-8. (PMID: 17317815)
Clin Cancer Res. 2005 Jan 1;11(1):206-16. (PMID: 15671548)
Lung Cancer. 2009 Jul;65(1):49-55. (PMID: 19100646)
Eur Radiol. 2014 Aug;24(8):1749-57. (PMID: 24889995)
Int Orthop. 2015 May;39(5):935-41. (PMID: 25743028)
J Neurooncol. 2018 Aug;139(1):135-143. (PMID: 29623552)
Cancer. 2007 Nov 15;110(10):2293-303. (PMID: 17896786)
Cancer Sci. 2018 Dec;109(12):3962-3970. (PMID: 30353601)
Development. 2018 Jul 20;145(14):. (PMID: 30030240)
Cancer Immunol Immunother. 2019 Jun;68(6):973-982. (PMID: 30963193)
Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. (PMID: 28232476)
J Cutan Pathol. 2008 Feb;35(2):192-6. (PMID: 18190444)
Cancer. 2013 May 15;119(10):1868-77. (PMID: 23401071)
Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. (PMID: 28119364)
Mol Oncol. 2018 Jan;12(1):3-20. (PMID: 29124875)
Histopathology. 2009 Dec;55(6):750-5. (PMID: 20002771)
Hum Pathol. 2017 Sep;67:60-68. (PMID: 28711648)
Cancer Sci. 2019 Oct;110(10):3038-3048. (PMID: 31385405)
Int J Mol Sci. 2017 May 30;18(6):. (PMID: 28556791)
Cancer Chemother Pharmacol. 2014 Feb;73(2):259-70. (PMID: 24253175)
J Surg Oncol. 2018 Nov;118(6):906-914. (PMID: 30212597)
J Clin Pathol. 2006 Jun;59(6):585-90. (PMID: 16461571)
Stroke. 2008 Oct;39(10):2845-52. (PMID: 18635859)
Cancer Immunol Immunother. 2020 Jul;69(7):1353-1362. (PMID: 32222780)
BMC Cancer. 2010 Jun 01;10:249. (PMID: 20515481)
Cancer. 2003 May 15;97(10):2530-43. (PMID: 12733153)
Diagn Mol Pathol. 2005 Sep;14(3):134-9. (PMID: 16106193)
Cancer Manag Res. 2019 Nov 27;11:10001-10009. (PMID: 31819633)
Oncotarget. 2016 Apr 19;7(16):21763-74. (PMID: 26943575)
Histopathology. 2007 Mar;50(4):448-52. (PMID: 17448020)
Clin Cancer Res. 2004 Apr 15;10(8):2824-31. (PMID: 15102691)
J Cancer Res Clin Oncol. 2014 Aug;140(8):1315-22. (PMID: 24804818)
Ann Surg Oncol. 2011 Oct;18(10):2841-50. (PMID: 21409488)
Eur J Cancer. 2019 Mar;110:98-106. (PMID: 30776758)
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1849-55. (PMID: 22723442)
Clin Cancer Res. 2011 Sep 15;17(18):5901-12. (PMID: 21821699)
Dis Markers. 2016;2016:4912405. (PMID: 27965519)
Br J Cancer. 2016 Aug 9;115(4):473-9. (PMID: 27434038)
Nat Med. 2007 Apr;13(4):504-9. (PMID: 17351626)
J Surg Oncol. 2019 Jun;119(8):1077-1086. (PMID: 30950072)
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448. (PMID: 30979742)
Int J Gynecol Cancer. 2015 May;25(4):622-8. (PMID: 25675041)
J Surg Oncol. 2011 Jun;103(8):773-81. (PMID: 21240992)
J Cancer Res Clin Oncol. 2002 Nov;128(11):610-6. (PMID: 12458341)
Eur J Cancer. 2013 Oct;49(15):3219-28. (PMID: 23835252)
Lancet. 2002 Jun 29;359(9325):2235-41. (PMID: 12103287)
Mod Pathol. 2012 Nov;25(11):1446-51. (PMID: 22743651)
Cancer Sci. 2019 May;110(5):1780-1789. (PMID: 30801864)
Indian J Orthop. 2018 Jan-Feb;52(1):35-44. (PMID: 29416168)
Proc SPIE Int Soc Opt Eng. 2020 Feb;11222:. (PMID: 32255887)
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):329-36. (PMID: 15823121)
Gynecol Oncol. 2007 Mar;104(3):524-8. (PMID: 17049587)
Eur J Cancer. 2013 Feb;49(3):684-95. (PMID: 23079473)
Med Oncol. 2016 Aug;33(8):93. (PMID: 27421997)
Orphanet J Rare Dis. 2015 Jan 23;10:6. (PMID: 25613038)
Cancer. 2005 May 1;103(9):1881-90. (PMID: 15772959)
Br J Cancer. 2009 Jul 7;101(1):71-9. (PMID: 19491901)
Eur J Surg Oncol. 2006 May;32(4):466-8. (PMID: 16524687)
Gynecol Oncol. 2011 May 1;121(2):323-7. (PMID: 21277011)
Ann Oncol. 2017 Mar 1;28(3):541-546. (PMID: 28426120)
Clin Cancer Res. 2013 Jul 15;19(14):3745-54. (PMID: 23674494)
Int J Mol Sci. 2020 Mar 29;21(7):. (PMID: 32235327)
Mol Pharm. 2017 May 1;14(5):1782-1789. (PMID: 28388076)
Curr Oncol. 2013 Jun;20(3):e247-54. (PMID: 23737694)
Eur J Cancer. 2018 Apr;93:28-36. (PMID: 29475197)
Clin Cancer Res. 2008 Nov 15;14(22):7223-36. (PMID: 19010839)
Cell Death Dis. 2014 May 08;5:e1213. (PMID: 24810049)
Oncologist. 2008 Apr;13(4):459-66. (PMID: 18448562)
J Clin Oncol. 2000 May;18(10):2087-94. (PMID: 10811674)
EBioMedicine. 2019 Jun;44:489-501. (PMID: 31221584)
Cancer. 1993 Jan 1;71(1):237-48. (PMID: 8416722)
J Surg Oncol. 2008 Jan 1;97(1):74-81. (PMID: 18041747)
Sci Rep. 2020 Feb 19;10(1):2915. (PMID: 32076024)
Lancet Oncol. 2013 Apr;14(4):371-82. (PMID: 23477833)
Genes Dev. 2008 May 15;22(10):1276-312. (PMID: 18483217)
Int J Cancer. 1985 Dec 15;36(6):689-93. (PMID: 2999006)
J Nucl Med. 2020 Jul 17;:. (PMID: 32680922)
Neoplasma. 2009;56(3):239-44. (PMID: 19309227)
J Nucl Med. 2020 May;61(5):655-661. (PMID: 31628218)
فهرسة مساهمة: Keywords: CD40; EGFR; IGF-1R; PDGFRα; TEM1; VEGFR-1; VEGFR-2; image guided surgery; near-infra red fluorescence; soft tissue sarcomas
تواريخ الأحداث: Date Created: 20210204 Latest Revision: 20210210
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7867119
DOI: 10.3390/cancers13030557
PMID: 33535618
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13030557